Abstract:BACKGROUND:The associations between the extent of forced expiratory volume in 1 s (FEV1) impairment and mortality, incident cardiovascular disease, and respiratory hospitalisations are unclear, and how these associations might vary across populations is unknown.METHODS:In this international, community-based cohort study, we prospectively enrolled adults aged 35-70 years who had no intention of moving residences for 4 years from rural and urban communities across 17 countries. A portable spirometer was used to assess FEV1. FEV1 values were standardised within countries for height, age, and sex, and expressed as a percentage of the country-specific predicted FEV1 value (FEV1%). FEV1% was categorised as no impairment (FEV1% ≥0 SD from country-specific mean), mild impairment (FEV1% <0 SD to -1 SD), moderate impairment (FEV1% <-1 SD to -2 SDs), and severe impairment (FEV1% <-2 SDs [ie, clinically abnormal range]). Follow-up was done every 3 years to collect information on mortality, cardiovascular disease outcomes (including myocardial infarction, stroke, sudden death, or congestive heart failure), and respiratory hospitalisations (from chronic obstructive pulmonary disease, asthma, pneumonia, tuberculosis, or other pulmonary conditions). Fully adjusted hazard ratios (HRs) were calculated by multilevel Cox regression.FINDINGS:Among 126 359 adults with acceptable spirometry data available, during a median 7·8 years (IQR 5·6-9·5) of follow-up, 5488 (4·3%) deaths, 5734 (4·5%) cardiovascular disease events, and 1948 (1·5%) respiratory hospitalisation events occurred. Relative to the no impairment group, mild to severe FEV1% impairments were associated with graded increases in mortality (HR 1·27 [95% CI 1·18-1·36] for mild, 1·74 [1·60-1·90] for moderate, and 2·54 [2·26-2·86] for severe impairment), cardiovascular disease (1·18 [1·10-1·26], 1·39 [1·28-1·51], 2·02 [1·75-2·32]), and respiratory hospitalisation (1·39 [1·24-1·56], 2·02 [1·75-2·32], 2·97 [2·45-3·60]), and this pattern persisted in subgroup analyses considering country income level and various baseline risk factors. Population-attributable risk for mortality (adjusted for age, sex, and country income) from mildly to moderately reduced FEV1% (24·7% [22·2-27·2]) was larger than that from severely reduced FEV1% (3·7% [2·1-5·2]) and from tobacco use (19·7% [17·2-22·3]), previous cardiovascular disease (5·5% [4·5-6·5]), and hypertension (17·1% [14·6-19·6]). Population-attributable risk for cardiovascular disease from mildly to moderately reduced FEV1 was 17·3% (14·8-19·7), second only to the contribution of hypertension (30·1% [27·6-32·5]).INTERPRETATION:FEV1 is an independent and generalisable predictor of mortality, cardiovascular disease, and respiratory hospitalisation, even across the clinically normal range (mild to moderate impairment).FUNDING:Population Health Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, Ontario Ministry of Health and Long-Term Care, AstraZeneca, Sanofi-Aventis, Boehringer Ingelheim, Servier, and GlaxoSmithKline, Novartis, and King Pharma. Additional funders are listed in the appendix.

Electric Fields in keV Electron Irradiated Polymers

Longitudinal Association of Economic Growth with Lung Function of Chinese Children and Adolescents over 30 Years: Evidence from Seven Successive National Surveys

Spirometric phenotypes from early childhood to young adulthood: a Chronic Airway Disease Early Stratification study

Plasticity of Individual Lung Function States from Childhood to Adulthood

Telomere length in circulating leukocytes is associated with lung function and disease

Lung Function Decline in Cystic Fibrosis: Impact of Data Availability and Modeling Strategies on Clinical Interpretations

Transfer factor, lung volumes, resistance and ventilation distribution in healthy adults

On Generalized k-Fractional Derivative Operator

Chromium speciation in liquid matrices: a survey of the literature

Lung function in young adulthood in relation to moderate-to-late preterm birth

Adult lung function and long-term air pollution exposure. ESCAPE: a multicentre cohort study and meta-analysis

Lung-function trajectories: relevance and implementation in clinical practice

Distinct trajectories of lung function from childhood to mid-adulthood

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of menopause: executive summary of recommendations.

Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations

Inter-Species Glia Differences: Implications for Successful Translation of Transgenic Rodent Alzheimer's Disease Model Treatment Using Bexarotene.

Smoking, respiratory symptoms, lung function and life expectancy: A longitudinal study of ageing

Structural Predictors of Lung Function Decline in Young Smokers with Normal Spirometry

Muscarinic acetylcholine receptors potentiate the GABAergic transmission in the developing rat inferior colliculus

Associations of improved air quality with lung function growth from childhood to adulthood: the BAMSE study

Mortality and Cardiovascular and Respiratory Morbidity in Individuals with Impaired FEV1 (PURE): an International, Community-Based Cohort Study.